High levels of circulating HMGB1 as a biomarker of acute liver failure in patients with viral hepatitis E

Liver International

Volumn 33, Issue 9, 2013, Pages 1341-1348

  Majumdar, Manasi ^a   Ratho, Radhakanta ^a   Chawla, Yogesh ^a   Singh, Mini P ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Acute liver failure; Cell mediated immunity; Hepatitis E virus; High mobility group box 1; Proliferation index

Indexed keywords

BIOLOGICAL MARKER; HIGH MOBILITY GROUP B1 PROTEIN;

ACUTE LIVER FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEPATITIS E; HOUSEKEEPING GENE; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION;

ACUTE LIVER FAILURE; CELL-MEDIATED IMMUNITY; HEPATITIS E VIRUS; HIGH-MOBILITY GROUP BOX 1; PROLIFERATION INDEX;

ADULT; BIOLOGICAL MARKERS; COLORIMETRY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS E; HMGB1 PROTEIN; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER FAILURE, ACUTE; MALE; REAL-TIME POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84883755734     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12197     Document Type: Article

References (32)

1. Aggarwal R, Jameel S. Hepatitis E vaccine. Hepatol Int 2008; 2: 308-15.
2. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981; 70: 252-55.
3. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India 2006; 19: 203-17.
4. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999; 19: 5237-46.
5. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
6. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001.
7. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
8. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99: 12351-6.
9. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001; 164: 1768-73.
10. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 2010; 1799: 141-8.
11. Nakahara T, Tsuruta R, Kaneko T, et al. High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage. Neurocrit Care 2009; 11: 362-8.
12. Li W, Sama AE, Wang H. Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol 2006; 6: 130-5.
13. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Diseases. New York: Grune & Stratton, 1970; 282-298.
14. Kumar S, Ratho RK, Chawla YK, Chakraborti A. The incidence of sporadic viral hepatitis in North India: a preliminary study. Hepatobiliary Pancreat Dis Int 2007; 6: 596-9.
15. Rana D, Menachery J, Chawla Y, et al. HBV specific T-cell responses in hepatitis B. Trop Gastroenterol 2011; 32: 273-8.
16. Huang LF, Yao YM, Dong N, et al. Association of high mobility group box-1 protein levels with sepsis and outcome of severely burned patients. Cytokine 2011; 53: 29-34.
17. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-9.
18. Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000; 9: 1651-63.
19. Wang H, Ward MF, Fan XG, Sama AE, Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006; 19: 3-9.
20. Kamau E, Takhampunya R, Li T, et al. Dengue virus infection promotes translocation of high mobility group box 1 protein from the nucleus to the cytosol in dendritic cells, upregulates cytokine production and modulates virus replication. J Gen Virol 2009; 90: 1827-35.
21. Cheng BQ, Jia CQ, Liu CT, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40: 446-52.
22. Liu HB, Fan XG, Huang JJ, et al. Serum level of HMGB1 in patients with hepatitis B and its clinical significance. Zhonghua Gan Zang Bing Za Zhi 2007; 15: 812-5.
23. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-60.
24. Zhou RR, Zhao SS, Zou MX, et al. HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol 2011; 11: 21.
25. Wang LW, Chen H, Gong ZJ. High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2010; 9: 499-507.
26. Majumdar M, Ratho R, Chawla Y, Singh MP. Evaluation of antigenicity and cell mediated immunity of Hepatitis E virus patients: using non radioactive MTT assay. Indian J Med Microbiol 2013; 31: 64-68.
27. Srivastava R, Aggarwal R, Sachdeva S, et al. Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. J Gastroenterol Hepatol 2011; 26: 306-11.
28. Saravanabalaji S, Tripathy AS, Dhoot RR, et al. Viral load, antibody titers and recombinant open reading frame 2 protein-induced TH1/TH2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis e. Intervirology 2009; 52: 78-85.
29. Mollica L, De Marchis F, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007; 14: 431-41.
30. Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H. Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther 2011; 339: 93-8.
31. Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol 2008; 28: 93-103.
32. Sitia G, Iannacone M, ller SM, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007; 81: 100-7.